Zydus Cadila To Enter Remdesivir Fray In India By End-July

Interferon Studies In Mexico, IND in US

Zydus Cadila hopes to launch its version of Gilead’s remdesivir by end-July in India, even as earlier licensees Hetero Drugs and Cipla have just commercialized the antiviral. Plans for pegylated interferon alfa-2b to treat COVID-19 include a trial in Mexico and an IND in the US. Separately, desidustat is being considered for additional indications.

Remdesivir
Zydus Cadila - Another Remdesivir Contender In The Wings • Source: Shutterstock

Zydus group's Cadila Healthcare Ltd. hopes to launch its version of Gilead Sciences Inc.’s investigational COVID-19 drug remdesivir in India by end-July, even as other early licensees Cipla Ltd. and Hetero Drugs Ltd. have just introduced the formulation in the country. Marketing approval for Zydus Cadila's brand of remdesivir is expected by mid-July.

Meanwhile, the company’s other COVID-19 candidates - a DNA vaccine and pegylated interferon alpha-2b - are also being fast-tracked.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip